Small Intestine | Stomach, Phase I

A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure

Volunteers
Health Professionals

What is the purpose of this trial?

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.

Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Sharon Huie

sharon.huie@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Hari Deshpande, MD
Associate Professor of Medicine (Medical Oncology); Clinical Research Team Leader Sarcoma, Medical Oncology; Director Medical Oncology Inpatient Consult Service, Medical Oncology

Sub-Investigator

Michelle Laspino

Last Updated
06/03/2025
Study HIC
#2000039616